AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
Tweet Send to a Friend
(Updated - August 11, 2026 9:40 AM EDT)
Truist Securities analyst Srikripa Devarakonda raised the price target on AbCellera ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Truist Securities analyst Srikripa Devarakonda raised the price target on AbCellera ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
